What is Wedbush’s Forecast for SYRE Q1 Earnings?

Spyre Therapeutics, Inc. (NASDAQ:SYRE) – Equities researchers at Wedbush issued their Q1 2025 earnings estimates for shares of Spyre Therapeutics in a research report issued on Friday, November 8th. Wedbush analyst D. Nierengarten forecasts that the company will earn ($0.84) per share for the quarter. Wedbush currently has a “Outperform” rating and a $45.00 target price on the stock. The consensus estimate for Spyre Therapeutics’ current full-year earnings is ($4.18) per share. Wedbush also issued estimates for Spyre Therapeutics’ Q2 2025 earnings at ($0.76) EPS, Q3 2025 earnings at ($0.73) EPS and Q4 2025 earnings at ($0.74) EPS.

A number of other equities analysts have also recently commented on SYRE. Guggenheim boosted their price target on Spyre Therapeutics from $50.00 to $65.00 and gave the stock a “buy” rating in a report on Friday, October 25th. Evercore ISI started coverage on Spyre Therapeutics in a research note on Tuesday, July 16th. They set an “outperform” rating for the company. Ten equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Spyre Therapeutics has a consensus rating of “Buy” and an average price target of $46.43.

Spyre Therapeutics Price Performance

Shares of SYRE opened at $35.82 on Monday. The firm has a 50 day simple moving average of $31.16 and a two-hundred day simple moving average of $30.42. Spyre Therapeutics has a one year low of $8.75 and a one year high of $47.97. The company has a market cap of $1.82 billion, a P/E ratio of -4.80 and a beta of 2.90.

Institutional Investors Weigh In On Spyre Therapeutics

A number of institutional investors have recently added to or reduced their stakes in SYRE. Amalgamated Bank acquired a new position in shares of Spyre Therapeutics during the second quarter worth $28,000. Quest Partners LLC acquired a new position in Spyre Therapeutics during the 2nd quarter worth about $36,000. SG Americas Securities LLC bought a new stake in shares of Spyre Therapeutics in the 2nd quarter valued at about $130,000. Carlyle Group Inc. acquired a new stake in shares of Spyre Therapeutics in the second quarter valued at about $227,000. Finally, Intech Investment Management LLC bought a new position in shares of Spyre Therapeutics during the third quarter worth about $246,000. 80.39% of the stock is owned by institutional investors.

About Spyre Therapeutics

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).